SAB BIOTHERAPEUTICS INC (SABS)
Health Care · Clinical-stage biopharmaceuticals / polyclonal antibody therapeutics · NASDAQ
SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1 diabetes.
What SAB BIOTHERAPEUTICS INC does
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, fully human immunoglobulin G (hIgG) antibodies to treat and prevent immune and autoimmune disorders. The company's proprietary Tc-Bovine (transchromosomic cattle) platform produces disease-targeted polyclonal human antibodies without requiring human plasma donors or convalescent plasma. The lead candidate, SAB-142, is a human anti-thymocyte globulin (hATG) in Phase 2b development for autoimmune type 1 diabetes (T1D), designed to slow disease progression and preserve insulin-producing beta cells.
Themes: autoimmune disease therapy, type 1 diabetes (T1D), immunotherapy, polyclonal antibodies, biologics production platform
Fundamentals
- Price$3.78 as of 2026-08-21 close
- Market cap$344M as of 2026-08-21
- 1-year return+83.9% 2025-08-21 close $2.06 → 2026-08-21 close $3.78
- P/E25.70 as of 2026-08-24
- Net margin-1795.8% as of 2026-08-24
- ROE+15.2% as of 2026-08-24
- Debt / equity0.01 as of 2026-08-24
- Beta0.60 as of 2026-08-24
- Last reported earnings2024-03-29 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How SABS compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SAB BIOTHERAPEUTICS INC looks technically
SAB BIOTHERAPEUTICS INC (SABS) is trading 0.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 17 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 9, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 11 trading days ago. It is 26.6% below its highest point of the past year. Trading volume is unusually light — only about 44% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 0.1% below its 200-day average, the long-term trend line — a long-term downtrend | -0.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.73 | $3.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.78 | $3.78 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 17 trading days ago — a "death cross", a bearish long-term signal | 17 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 9, below the 25 that marks a real trend) | 9.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.0 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($3.61 to $3.97) — its "stochastic" reading is 47 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 47.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.15 | $5.15 |
|---|---|---|
| From the 52-week high | it is 26.6% below its 52-week high (its highest price of the past year) | -26.6% |
| Above the 52-week low | it is 104.3% above its 52-week low (its lowest price of the past year) | +104.3% |
| Below the 52-week high | it is 26.6% below its highest point of the past year | 26.6% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 49 trading days ago | 49 sessions |
| All-time high | its highest closing price on record is $129.00 (set on 2021-10-22) | $129.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.95 to $4.59), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.87 to $2.96. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.7% |
| From the all-time high | it is 97.1% below its all-time high | -97.1% |
| Nearest price level | it is sitting right on a support level at $3.76 — a price it turned at twice since 2026-02-06, most recently on 2026-07-21. Since 2024-08-21 it has 12 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $1.00 (set on 2025-04-04) | $1.00 |
| Above the all-time low | it is 278.0% above its all-time low | +278.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1616 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1616 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.45 and $3.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.45 – $3.71 – $3.98 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is sitting essentially on its 200-day average price (0.1% below it in plain percentage terms) | at its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 44% of its 30-day average | 0.44× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 5.4% above the previous close 47 sessions ago and has not traded back through the level it left behind at 3.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.4% |
| Gap filled | a 2.3% gap down opened on 2026-07-17 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 1.5 percentage points (the stock gained 3.8% while the market gained 2.3%) | +1.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.9 percentage points (the stock lost 0.8% while the market gained 3.1%) | -3.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.2 percentage points (the stock gained 5.9% while the market gained 11.1%) | -5.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 63.5 percentage points (the stock gained 83.9% while the market gained 20.5%) | +63.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 4.7% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.89 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -2.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $3.78 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -0.1% |
Price levels it has turned at before
SABS last closed at $3.78 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.76 | Support | 0.5% below the last close | turned there twice · 2026-02-06 to 2026-07-21 |
| $3.67 | Support | 3.0% below the last close | turned there four times · 2026-03-06 to 2026-06-26 |
| $3.97 | Resistance | 5.1% above the last close | turned there twice · 2026-05-22 to 2026-08-04 |
| $3.51 | Support | 7.1% below the last close | turned there three times · 2025-12-30 to 2026-07-07 |
| $4.07 | Resistance | 7.6% above the last close | turned there four times · 2025-12-19 to 2026-07-06 |
| $4.19 | Resistance | 10.8% above the last close | turned there four times · 2025-11-28 to 2026-06-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.09 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$11.64 range $6.00 – $16.00; median $12.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SABS
- Consensus EPS estimate-$0.2688 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: SAB-142 is still in Phase 2b (SAFEGUARD) trials; failure to meet efficacy or safety endpoints could delay or derail regulatory approval","Regulatory pathway risk: Polyclonal antibodies (pAbs) follow a different regulatory path (CBER vs. CDER) than monoclonal antibodies; any adverse precedent or regulatory change could impact approval timeline","Financial sustainability risk: Company is unprofitable with significant R&D spending (Q1 2026: $13.4M) and limited runway; dependence on capital markets for funding clinical programs"]
What changed in the latest 10-Q
AI-assisted comparison of SABS's 10-Q filed 2026-05-12 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds: 'potentially disease-modifying' descriptor for SAB-142 in lead product candidate section (filed 2026-05-12)
- Newer filing adds: 'redosable immunotherapy' characteristic for SAB-142 (filed 2026-05-12)
- Newer filing adds: 'multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG)' description (filed 2026-05-12)
- Newer filing adds: 'directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of "bad acting" T-lymphocytes' mechanism detail (filed 2026-05-12)
- Newer filing adds: specific reference to 'data from more than 800 human subjects have been treated' (filed 2026-05-12)
- Newer filing adds: 'we have seen no serum sickness rate and no incidence of neutralizing anti-drug antibodies (ADA)' statement (filed 2026-05-12)
- Newer filing adds: expanded regulatory pathway discussion mentioning FDA, MHRA, and TGA (filed 2026-05-12)
- Newer filing adds: detailed explanation of CBER vs CDER regulatory distinction for polyclonal vs monoclonal antibodies (filed 2026-05-12)
- Removed:
- Older filing contained: 'hIgGs' instead of 'hIgG' in Company Overview (filed 2025-11-14)
- Older filing contained: reference to 'internally discovered antibodies' and specific description of multi-specificity in Company Overview (filed 2025-11-14)
- Older filing contained: 'without the need for human donors or convalescent plasma' in Company Overview opening (filed 2025-11-14)
- Older filing contained: 'first-in-class, multi-target hATG treatment designed to provide superior efficacy and safety' descriptor (filed 2025-11-14)
- Older filing contained: reference to Stage 2 T1D in SAB-142 indication (filed 2025-11-14)
- Older filing contained: reference to 'more than 700 human subjects' treated with platform antibodies (filed 2025-11-14)
- Older filing contained: 'support the expectation of a zero-serum sickness rate and a zero incidence' language (filed 2025-11-14)
- Older filing contained: detailed references to IND clearance date (May 2024), Phase 1 positive data announcement (January 2025), and FDA Type B meeting (May 29, 2025) (filed 2025-11-14)
- Older filing contained: reference to SAFEGUARD study design discussion and FDA guidance (filed 2025-11-14)
- Older filing contained: 'Other Immunology Indications' section discussing T- and B-cell dysregulation in 80+ autoimmune diseases (filed 2025-11-14)
- Reworded:
- Changed from 'involved known and unknown risks' to 'involve known and unknown risks' in forward-looking statements section (filed 2026-05-12)
- Shifted Company Overview description: moved 'without the need for human donors or convalescent plasma' from opening sentence to later in proprietary platform discussion (filed 2026-05-12)
- Changed SAB-142 description from 'human anti-thymocyte globulin (hATG) focused on preventing or delaying' to 'a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D)' (filed 2026-05-12)
- Removed 'first-in-class, multi-target hATG treatment designed to provide superior efficacy and safety in delaying the onset or progression of T1D' language and replaced with mechanistic/clinical validation focus (filed 2026-05-12)
- Changed indication scope from 'Stage 3 or Stage 2 T1D' to focus on 'Stage 3 T1D patients' only (filed 2026-05-12)
- Changed from 'Tc Bovine' to 'Tc-Bovine' hyphenation (filed 2026-05-12)
- Notes:
- The newer filing text appears truncated at the end of the SAB-142 section, cutting off mid-sentence regarding regulatory pathway details
- The older filing text also appears truncated at the end, cutting off discussion of Phase 2 progression in other indications
- Full comparison of remaining MD&A sections not possible due to truncation in both documents
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SABS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding SABS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 445,157
- Reported value $1,704,952
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SABS had 4,660,515 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SABS had 5.12% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.95 days to cover at the same settlement.
- Reported short interest (shares) 4,660,515
- Short interest (% of shares outstanding) 5.12%
- Prior settlement (shares) 4,376,175
- Reported change 6.5%
- Days to cover (reported) 8.95
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thymoglobulin / Genzyme (rabbit ATG, the established clinical comparator)
- Sanofi (owns Genzyme/Thymoglobulin)
- Regeneron Pharmaceuticals (immune/autoimmune antibodies)
- Momenta Pharmaceuticals (polyclonal and antibody therapeutics)
- Vertex Pharmaceuticals (cell therapy and immune disorders)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SABS vs…
SAB BIOTHERAPEUTICS INC is found in…
Frequently asked questions
What does SAB BIOTHERAPEUTICS INC (SABS) do?
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, fully human immunoglobulin G (hIgG) antibodies to treat and prevent immune and autoimmune disorders. The company's proprietary Tc-Bovine (transchromosomic cattle) platform produces disease-targeted polyclonal human antibodies without requiring human plasma donors or convalescent plasma.
What sector is SAB BIOTHERAPEUTICS INC (SABS) in?
SAB BIOTHERAPEUTICS INC (SABS) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceuticals / polyclonal antibody therapeutics. It trades on NASDAQ.
Who are SAB BIOTHERAPEUTICS INC's (SABS) competitors?
Notable peers of SAB BIOTHERAPEUTICS INC (SABS) include Thymoglobulin / Genzyme (rabbit ATG, the established clinical comparator), Sanofi (owns Genzyme/Thymoglobulin), Regeneron Pharmaceuticals (immune/autoimmune antibodies), Momenta Pharmaceuticals (polyclonal and antibody therapeutics) and Vertex Pharmaceuticals (cell therapy and immune disorders). This peer set is informational only — not financial advice.
Is SAB BIOTHERAPEUTICS INC (SABS) overbought or oversold right now?
SAB BIOTHERAPEUTICS INC (SABS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SABS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.